Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 183

1.

The Relevance of Vitamin and Iron Deficiency in Patients with Inflammatory Bowel Diseases in Patients of the Swiss IBD Cohort.

Madanchi M, Fagagnini S, Fournier N, Biedermann L, Zeitz J, Battegay E, Zimmerli L, Vavricka SR, Rogler G, Scharl M; Swiss IBD Cohort Study Group .

Inflamm Bowel Dis. 2018 Apr 13. doi: 10.1093/ibd/izy054. [Epub ahead of print]

PMID:
29669023
2.

Genetic polymorphisms associated with smoking behaviour predict the risk of surgery in patients with Crohn's disease.

Lang BM, Biedermann L, van Haaften WT, de Vallière C, Schuurmans M, Begré S, Zeitz J, Scharl M, Turina M, Greuter T, Schreiner P, Heinrich H, Kuntzen T, Vavricka SR, Rogler G, Beerenwinkel N, Misselwitz B; Swiss IBD Cohort Study Group.

Aliment Pharmacol Ther. 2018 Jan;47(1):55-66. doi: 10.1111/apt.14378. Epub 2017 Oct 20.

PMID:
29052254
3.

Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study.

Vavricka SR, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, Protic M, Michetti P, Straumann A, Fournier N, Juillerat P, Biedermann L, Zeitz J, Misselwitz B, Scharl M, Heinrich H, Manser CN, Safroneeva E, Raja Ali RA, Rogler G, Schoepfer AM, Greuter T; Swiss IBD Cohort Study Group.

Inflamm Bowel Dis. 2017 Jul;23(7):1174-1181. doi: 10.1097/MIB.0000000000001109.

4.

Patient self-reported concerns in inflammatory bowel diseases: A gender-specific subjective quality-of-life indicator.

Pittet V, Vaucher C, Froehlich F, Burnand B, Michetti P, Maillard MH; Swiss IBD Cohort Study Group.

PLoS One. 2017 Feb 10;12(2):e0171864. doi: 10.1371/journal.pone.0171864. eCollection 2017.

5.

Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease: Prevalence, Presentation, and Anti-TNF Treatment.

Greuter T, Bertoldo F, Rechner R, Straumann A, Biedermann L, Zeitz J, Misselwitz B, Scharl M, Rogler G, Safroneeva E, Ali RAR, Braegger C, Heyland K, Mueller P, Nydegger A, Petit LM, Schibli S, Furlano RI, Spalinger J, Schäppi M, Zamora S, Froehlich F, Herzog D, Schoepfer AM, Vavricka SR; Swiss IBD Cohort Study Group.

J Pediatr Gastroenterol Nutr. 2017 Aug;65(2):200-206. doi: 10.1097/MPG.0000000000001455.

6.

Experts Opinion on the Practical Use of Azathioprine and 6-Mercaptopurine in Inflammatory Bowel Disease.

Mottet C, Schoepfer AM, Juillerat P, Cosnes J, Froehlich F, Kessler-Brondolo V, Seibold F, Rogler G, Vavricka SR, Michetti P.

Inflamm Bowel Dis. 2016 Nov;22(11):2733-2747.

7.

Patients and gastroenterologists' perceptions of treatments for inflammatory bowel diseases: do their perspectives match?

Vaucher C, Maillard MH, Froehlich F, Burnand B, Michetti P, Pittet V.

Scand J Gastroenterol. 2016 Sep;51(9):1056-61. doi: 10.3109/00365521.2016.1147065. Epub 2016 Feb 19.

PMID:
26891800
8.

Symptoms of Depression and Anxiety Are Independently Associated With Clinical Recurrence of Inflammatory Bowel Disease.

Mikocka-Walus A, Pittet V, Rossel JB, von Känel R; Swiss IBD Cohort Study Group.

Clin Gastroenterol Hepatol. 2016 Jun;14(6):829-835.e1. doi: 10.1016/j.cgh.2015.12.045. Epub 2016 Jan 25.

PMID:
26820402
9.

Quality of Life in Swiss Paediatric Inflammatory Bowel Disease Patients: Do Patients and Their Parents Experience Disease in the Same Way?

Mueller R, Ziade F, Pittet V, Fournier N, Ezri J, Schoepfer A, Schibli S, Spalinger J, Braegger C, Nydegger A; Swiss IBD Cohort Study.

J Crohns Colitis. 2016 Mar;10(3):269-76. doi: 10.1093/ecco-jcc/jjv199. Epub 2015 Oct 29.

10.

Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease.

Safroneeva E, Vavricka SR, Fournier N, Pittet V, Peyrin-Biroulet L, Straumann A, Rogler G, Schoepfer AM; Swiss IBD Cohort Study Group.

Aliment Pharmacol Ther. 2015 Oct;42(8):977-89. doi: 10.1111/apt.13363. Epub 2015 Aug 14.

11.

Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients.

Safroneeva E, Vavricka S, Fournier N, Seibold F, Mottet C, Nydegger A, Ezri J, Straumann A, Rogler G, Schoepfer AM; Swiss IBD Cohort Study Group.

Aliment Pharmacol Ther. 2015 Sep;42(5):540-8. doi: 10.1111/apt.13307. Epub 2015 Jul 6. Erratum in: Aliment Pharmacol Ther. 2015 Dec;42(11-12):1334.

12.

Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort.

Vavricka SR, Rogler G, Gantenbein C, Spoerri M, Prinz Vavricka M, Navarini AA, French LE, Safroneeva E, Fournier N, Straumann A, Froehlich F, Fried M, Michetti P, Seibold F, Lakatos PL, Peyrin-Biroulet L, Schoepfer AM.

Inflamm Bowel Dis. 2015 Aug;21(8):1794-800. doi: 10.1097/MIB.0000000000000429.

13.

Aqueous black colloids of reticular nanostructured gold.

Stanca SE, Fritzsche W, Dellith J, Froehlich F, Undisz A, Deckert V, Krafft C, Popp J.

Sci Rep. 2015 Jan 20;5:7899. doi: 10.1038/srep07899.

14.

Acceptance of inflammatory bowel disease treatment recommendations based on appropriateness ratings: do practicing gastroenterologists agree with experts?

Pittet V, Maillard MH, Lauvergeon S, Timmer M, Michetti P, Froehlich F, Burnand B, Vader JP, Mottet C.

J Crohns Colitis. 2015 Feb;9(2):132-9.

PMID:
25518062
15.

Factors associated with durable response to infliximab in Crohn's disease 5 years and beyond: a multicenter international cohort.

Juillerat P, Sokol H, Froehlich F, Yajnik V, Beaugerie L, Lucci M, Burnand B, Macpherson AJ, Cosnes J, Korzenik JR.

Inflamm Bowel Dis. 2015 Jan;21(1):60-70. doi: 10.1097/MIB.0000000000000225.

PMID:
25517594
16.

The gap between scientific evidence and clinical practice: 5-aminosalicylates are frequently used for the treatment of Crohn's disease.

Schoepfer AM, Bortolotti M, Pittet V, Mottet C, Gonvers JJ, Reich O, Fournier N, Vader JP, Burnand B, Michetti P, Froehlich F.

Aliment Pharmacol Ther. 2014 Oct;40(8):930-7. doi: 10.1111/apt.12929. Epub 2014 Aug 22.

17.

Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort.

Hiroz P, Vavricka SR, Fournier N, Safroneeva E, Pittet V, Rogler G, Schoepfer AM; Swiss Inflammatory Bowel Diseases Cohort Study Group.

Scand J Gastroenterol. 2014 Oct;49(10):1207-18. doi: 10.3109/00365521.2014.946082. Epub 2014 Aug 14.

PMID:
25120029
18.

IR spectroscopic methods for the investigation of the CO release from CORMs.

Klein M, Neugebauer U, Gheisari A, Malassa A, Jazzazi TM, Froehlich F, Westerhausen M, Schmitt M, Popp J.

J Phys Chem A. 2014 Jul 24;118(29):5381-90. doi: 10.1021/jp503407u. Epub 2014 Jul 10.

PMID:
24978105
19.

Prevalence and clinical importance of mesenteric venous thrombosis in the Swiss Inflammatory Bowel Disease Cohort.

Violi NV, Schoepfer AM, Fournier N, Guiu B, Bize P, Denys A; Swiss Inflammatory Bowel Disease Cohort Study Group.

AJR Am J Roentgenol. 2014 Jul;203(1):62-9. doi: 10.2214/AJR.13.12447. Erratum in: AJR Am J Roentgenol. 2014 Aug;203(2):463.

PMID:
24951196
20.

Diagnostic yield of endoscopy in patients with abdominal complaints: incremental value of faecal calprotectin on guidelines of appropriateness.

Burri E, Manz M, Schroeder P, Froehlich F, Rossi L, Beglinger C, Lehmann FS.

BMC Gastroenterol. 2014 Mar 29;14:57. doi: 10.1186/1471-230X-14-57.

Supplemental Content

Loading ...
Support Center